E 2051Alternative Names: E2051
Latest Information Update: 06 Aug 2007
At a glance
- Originator Eisai Co Ltd
- Mechanism of Action Calcium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cerebral infarction
Most Recent Events
- 17 Sep 2003 Phase-I clinical trials in Cerebral infarction in USA (unspecified route)
- 10 Sep 2002 Preclinical trials in Cerebral infarction in Japan (unspecified route)